A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Tridesilon Pharmacology, Pharmacokinetics, Studies, Metabolism - Desonide
Tridesilon Pharmacology, Pharmacokinetics, Studies, Metabolism - Desonide
CLINICAL PHARMACOLOGY
Like other topical
corticosteroids, desonide has anti- inflammatory, antipruritic and
vasoconstrictive
properties. The mechanism
of the anti-inflammatory activity of the topical
steroids, in general, is unclear. However corticosteroids are thought
to act by the induction
of phospholipase
A2 inhibitory proteins, collectively called lipocortins.
It is postulated that these proteins control
the biosynthesis
of potent mediators of
inflammation such
as prostaglandins and leukotrienes by inhibiting the release
of their common precursor arachidonic acid. Arachidonic acid
is released from membrane phospholipids by phospholipase
A2.
Pharmacokinetics
The extent of percutaneous
absorption of topical
corticosteroids is determined by many factors including the vehicle
and the integrity of the epidermal barrier. Occlusive dressings
with hydrocortisone
for up to 24 hours have not been demonstrated to increase penetration;
however, occlusion of hydrocortisone
for 96 hours markedly enhances penetration. Topical corticosteroids
can be absorbed from normal
intact skin, inflammation
and/or other disease processes in the skin
may increase percutaneous
absorption. Studies performed with DesOwen (desonide cream, ointment
and lotion) Cream, Ointment, and Lotion indicate that they are in
the low to medium range
of potency as compared wth other topical
corticosteroids.
top
